Marlene Wright Barton
Presidente presso Wright Regulatory Consulting LLC
Posizioni attive di Marlene Wright Barton
Società | Posizione | Inizio | Fine |
---|---|---|---|
Revival Healthcare Capital LLC
Revival Healthcare Capital LLC Investment ManagersFinance Revival Healthcare Capital LLC (Revival Healthcare Capital) is a private equity firm founded in 2018. The firm is headquartered in Austin, Texas. | Consulente / Consigliere | - | - |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | Responsabile della Conformità | 01/12/2021 | - |
Corporate Officer/Principal | 01/12/2021 | - | |
Wright Regulatory Consulting LLC | Presidente | 01/09/2020 | - |
WRC LLC | Presidente | 01/01/2010 | - |
Storia della carriera di Marlene Wright Barton
Precedenti posizioni note di Marlene Wright Barton
Società | Posizione | Inizio | Fine |
---|---|---|---|
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. | Responsabile della Conformità | 01/10/2018 | 01/09/2020 |
Corporate Officer/Principal | 01/10/2018 | 01/09/2020 | |
PTV Sciences LP
PTV Sciences LP Investment ManagersFinance PTV Sciences LP (PTV Healthcare Capital) is a venture capital firm founded in 2003 by Matthew S. Crawford and Evan S. Melrose. The firm is headquartered in Houston, Texas. | Investitore di Private Equity | - | - |
Formazione di Marlene Wright Barton
SUNY Empire State College | Graduate Degree |
State University of New York at Binghamton | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Israele | 2 |
Posizioni
Compliance Officer | 2 |
Corporate Officer/Principal | 2 |
President | 2 |
Settori
Consumer Services | 3 |
Finance | 3 |
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 6 |
---|---|
PTV Sciences LP
PTV Sciences LP Investment ManagersFinance PTV Sciences LP (PTV Healthcare Capital) is a venture capital firm founded in 2003 by Matthew S. Crawford and Evan S. Melrose. The firm is headquartered in Houston, Texas. | Finance |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. | Health Technology |
Revival Healthcare Capital LLC
Revival Healthcare Capital LLC Investment ManagersFinance Revival Healthcare Capital LLC (Revival Healthcare Capital) is a private equity firm founded in 2018. The firm is headquartered in Austin, Texas. | Finance |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | Health Technology |
Wright Regulatory Consulting LLC | |
WRC LLC |